Q4 2025 Dyadic International Inc Earnings Call Transcript
Key Points
- Dyadic International Inc (DYAI) has successfully transitioned from a development-stage platform company to a commercial product-driven biotechnology business.
- The company has launched its first commercial product, recombinant human albumin, in partnership with Proliant Health & Biologicals, which is expected to generate recurring revenue.
- Dyadic has secured multiple revenue-generating partnerships and distribution agreements, enhancing its market penetration and sales potential.
- The company is advancing its product portfolio in life sciences, food and nutrition, and bioindustrial segments, targeting large and growing markets.
- Dyadic's collaborations in biopharmaceuticals, including with the Gates Foundation and CEPI, are progressing well, with promising data supporting further development.
- Total revenue for 2025 decreased to $3.09 million from $3.5 million in 2024, primarily due to lower R&D collaboration activity and reduced license and milestone revenue.
- The company reported a net loss of $7.36 million for 2025, an increase from the $5.81 million net loss in 2024.
- Despite progress, Dyadic's financials still reflect a transition phase, with the company not yet achieving profitability.
- The commercialization of new products is expected to be a slow ramp-up, as products need to be qualified for use in customer workflows.
- There is uncertainty regarding the timing of reaching breakeven, as it depends on the successful commercialization and adoption of new products.
Good evening, and welcome to Dyadic International full year 2025 conference call. (Operator Instructions) As a reminder, this conference call is being recorded today, March 25, 2026. I would now like to turn the call over to Ms. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead.
Thank you, operator. Good evening, and welcome, everyone, to Dyadic's full-year 2025 conference call. I hope you have had the opportunity to review Dyadic's press releases announcing financial results for the year ended December 31, 2025. You may access our release and Form 10-K under the Investors section of the company's website at dyadic.com.
On today's call, our President and Chief Operating Officer, Joe Hazelton will review our full year 2025 business and corporate highlights and provide a commentary on the strategic direction of the business. Our CEO, Mark Emalfarb, will provide an update on our biopharmaceutical programs, and I will follow with a review of our financial results in more detail.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
